8-K: Premier Stockholders Approve Patient Square Capital Acquisition

Premier, Inc. stockholders overwhelmingly approved the acquisition by an affiliate of Patient Square Capital for $28.25 per share, with the transaction expected to close around November 25, 2025.

Summary

• Premier, Inc. held a special meeting on November 21, 2025, where stockholders voted on proposals related to the merger with Premium Parent, LLC, an affiliate of Patient Square Capital.
• The Merger Agreement was adopted with 64,965,155 votes for, 52,235 against, and 486,484 abstained. This represents approximately 99% of shares voted and 79% of total outstanding shares.
• Stockholders also approved, on an advisory (non-binding) basis, the compensation for named executive officers in connection with the merger, with 50,579,097 votes for, 14,497,546 against, and 427,231 abstained.
• The merger is expected to be consummated on or about November 25, 2025, subject to customary closing conditions.
• Under the terms, Premier stockholders will receive $28.25 in cash per share, representing a 23.8% premium to the 60-day volume-weighted average price as of September 5, 2025.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the overwhelming stockholder approval of the merger at a significant premium, indicating a successful outcome for shareholders and a clear path to closing the transaction.

Positives

• Overwhelming stockholder approval (approximately 99% of votes cast) for the merger agreement.
• The acquisition price of $28.25 per share represents a significant 23.8% premium to the 60-day volume-weighted average price as of September 5, 2025.
• The transaction is on track to close quickly, expected on or about November 25, 2025.

Negatives

• A significant number of stockholders (14,497,546 votes) voted against the advisory proposal for executive compensation related to the merger, indicating some dissent regarding executive payouts.

Risks

• Inability to consummate the Merger within the anticipated time period, or at all, due to failure to obtain required regulatory approvals, satisfy other conditions, or complete contemplated financing arrangements.
• Adverse effects on the market price of Premier Class A Common Stock due to merger-related announcements.
• Disruption from the Merger making it more difficult to maintain business and operational relationships, including retaining and hiring key personnel and maintaining relationships with customers, vendors, and other business partners.
• Occurrence of any event, change, or other circumstances that could give rise to the termination of the Merger Agreement.
• Risks related to disruption of current plans and operations or the diversion of management's attention from ongoing business operations due to the Merger.
• Significant transaction costs associated with the merger.
• Risk of litigation and/or regulatory actions related to the Merger or unfavorable results from currently pending or future litigation and proceedings.

Future Outlook

The merger is expected to be consummated on or about November 25, 2025, subject to the satisfaction or waiver of remaining customary closing conditions.

Management Comments

• Premier stockholders overwhelmingly approved the previously announced acquisition of the Company by an affiliate of Patient Square Capital.
• Approximately 99% of shares voted were voted in favor of the transaction.

Industry Context

Premier, Inc. operates as a technology-driven health care improvement company, uniting providers, suppliers, payers, and policymakers. This acquisition by Patient Square Capital, a dedicated health care investment firm, reflects a broader trend of private equity firms investing in specialized healthcare technology and services to drive efficiency and innovation, often seeking to optimize operations and leverage data analytics in a rapidly evolving industry landscape.

Comparison to Industry Standards

• The 23.8% premium offered to Premier stockholders is a strong indicator of value, often exceeding typical premiums in similar healthcare technology acquisitions, which can range from 15% to 30% depending on market conditions and strategic fit.
• The overwhelming stockholder approval (99% of votes cast) suggests that the deal terms were well-received, aligning with or exceeding typical approval rates for strategic acquisitions in the healthcare sector, which often require significant shareholder consensus.
• The rapid timeline from merger agreement (September 21, 2025) to expected closing (November 25, 2025) indicates efficient regulatory and shareholder approval processes, comparable to well-structured transactions in the industry.

Stakeholder Impact

• Shareholders: Will receive $28.25 cash per share, representing a 23.8% premium, providing a clear exit and immediate return on investment.
• Employees: Potential disruption from the merger, making it more difficult to retain and hire key personnel, as noted in the risks.
• Customers, Vendors, and Business Partners: Potential disruption from the merger making it more difficult to maintain existing business and operational relationships, as noted in the risks.

Next Steps

• Consummation of the Merger on or about November 25, 2025, subject to satisfaction or waiver of remaining customary closing conditions.
• Filing of final voting results in a Form 8-K by Premier with the U.S. Securities and Exchange Commission.

Key Dates

Recommendation

The overwhelming stockholder approval of the merger at a substantial 23.8% premium to the recent trading price, coupled with an imminent closing date, makes this a strong buy for arbitrageurs or investors seeking a quick, low-risk return by acquiring shares below the $28.25 cash offer price before the transaction closes. For long-term investors, the acquisition provides a clear exit at a favorable valuation.

Keywords

Premier Inc, PINC, Patient Square Capital, Merger, Acquisition, Healthcare Technology, Stockholder Vote, Special Meeting, Cash Per Share, Premium, Corporate Action